Drug developer Pfizer Inc. is paying Protalix BioTherapeutics Inc. $60 million upfront for licensing rights to a developing Gaucher's disease treatment, the companies said on Tuesday.
Pfizer signs development deal with ProtalixCourtesy Newsvine - business Tue, 12/01/2009 - 05:56
Drug developer Pfizer Inc. is paying Protalix BioTherapeutics Inc. $60 million upfront for licensing rights to a developing Gaucher's disease treatment, the companies said on Tuesday. Related itemsPfizer extends Icagen stock tender offer by a day
Pfizer boosts dividend 11 percent
Pfizer to pay $14.5M to settle marketing charges
Panasonic BB-GT1540B Globarange Expandable Cordless...
Panasonic Dect 6.0 Expandable Silver Digital Cordless...
|
Popular by tags WeekMonth |
Post new comment